Home/Filings/4/0001193125-25-225133
4//SEC Filing

Mulay James 4

Accession 0001193125-25-225133

CIK 0001991792other

Filed

Sep 29, 8:00 PM ET

Accepted

Sep 30, 4:38 PM ET

Size

8.6 KB

Accession

0001193125-25-225133

Insider Transaction Report

Form 4
Period: 2025-09-29
Mulay James
Director
Transactions
  • Sale

    Common Stock

    2025-09-29$39.19/sh12,755$499,8680 total
  • Exercise/Conversion

    Director Stock Option (right to buy)

    2025-09-2912,7550 total
    Exercise: $1.82Exp: 2031-07-18Common Stock (12,755 underlying)
  • Exercise/Conversion

    Common Stock

    2025-09-29$1.82/sh+12,755$23,21412,755 total
Footnotes (3)
  • [F1]The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.99 to $39.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F3]Fully vested

Documents

1 file

Issuer

CG Oncology, Inc.

CIK 0001991792

Entity typeother

Related Parties

1
  • filerCIK 0001684531

Filing Metadata

Form type
4
Filed
Sep 29, 8:00 PM ET
Accepted
Sep 30, 4:38 PM ET
Size
8.6 KB